PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH : Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –February 28, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Mar. 7, 2018-- Regulatory News : ERYTECH (Euronext: ERYP- Nasdaq: ERYP) Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq
View HTML
Toggle Summary ERYTECH : Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –February 28, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Mar. 7, 2018-- Regulatory News : ERYTECH (Euronext: ERYP- Nasdaq: ERYP) Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq
View HTML
Toggle Summary ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
LYON, France and CAMBRIDGE, Mass. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three
View HTML
Toggle Summary ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
LYON, France --(BUSINESS WIRE)--Apr. 24, 2018-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform,
View HTML
Toggle Summary ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
LYON, France --(BUSINESS WIRE)--Apr. 24, 2018-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform,
View HTML
Toggle Summary ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
(GLOBE NEWSWIRE via COMTEX) --- Focuses development efforts on solid tumor indications - Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer.
View HTML
Toggle Summary ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018
LYON, France and CAMBRIDGE, Mass., July  17, 2018  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq: ERYP ) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were
View HTML
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – January 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Feb. 12, 2018-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – January 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Feb. 12, 2018-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –December 31, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Jan. 8, 2018-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Top